Dr. Francesco Lo-Coco on Arsenic Trioxide in APL

Video

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in the rare hematological cancer acute promyelocytic leukemia (APL).

Currently, all-trans retinoic acid (ATRA) plus chemotherapy is the gold standard for newly diagnosed APL patients demonstrating an 80% cure rate and typical toxicities (myelosuppression infections, hair loss). In the past 10 to 15 years, Lo-Coco says, ATO was suggested by Chinese investigators to show efficacy in APL with inferior toxicity.

A phase III trial analyzing ATRA and ATO versus ATRA and idarubicin (AIDA) in newly diagnosed, non high-risk APL showed that the new strategy is at least equal effective.

<<<

View coverage from the 2012 ASH Meeting

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD